ML390

• Description :

  ML390 is a potent dihydroorotate dehydrogenase (DHODH) inhibitor. ML390 is an inducer of myeloid differentiation and causes myeloid differentiation in murine (ER-HoxA9) and human (U937 and THP1) acute myeloid leukemia (AML) models[1][2][3].

• CAS Number :

  [2029049-79-2]

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  Dihydroorotate Dehydrogenase

• Type :

  Reference compound

• Related Pathways :

  Metabolic Enzyme/Protease

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/ML390.html

• Concentration :

  10mM

• Purity :

  99.72

• Solubility :

  DMSO : ≥ 27 mg/mL

• Smiles :

  O=C(NCCC(N[C@H]1C(C=CC=C2)=C2CCC1)=O)C3=CC=C(OC(F)(F)F)C=C3

• Molecular Formula :

  C21H21F3N2O3

• Molecular Weight :

  406.40

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Sykes DB et al. Discovering Small Molecules that Overcome Differentiation Arrest in Acute Myeloid Leukemia. National Center for Biotechnology Information (US) ; 2010-2013 Dec 15.|[2]David B Sykes, et al. Inhibition of Dihydroorotate Dehydrogenase Overcomes Differentiation Blockade in Acute Myeloid Leukemia. Cell. 2016 Sep 22;167 (1) :171-186.e15.|[3]Timothy A Lewis, et al. Development of ML390: A Human DHODH Inhibitor That Induces Differentiation in Acute Myeloid Leukemia. ACS Med Chem Lett. 2016 Sep 28;7 (12) :1112-1117.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported